Endocrinology, Vol 136, 5651-5658, Copyright © 1995 by Endocrine Society

ARTICLES

The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent

A Souque, J Fagart, B Couette, E Davioud, F Sobrio, A Marquet and ME Rafestin-Oblin
INSERM U-246, Faculte de Medecine Xavier Bichat, Paris, France.

To investigate the role of the C18 substituents in the agonist/antagonist properties of mineralocorticoids, the activities of certain C18-substituted progesterone (P) derivatives were examined. These compounds were characterized by an unsaturated side-chain in the case of 18-vinylprogesterone (18VP) and 18-ethynylprogesterone (18EP) and by an enone group in the case of 18-oxo-18-vinylprogesterone (18OVP). P and its 18-substituted derivatives bind to the recombinant human MR (hMR) overexpressed in Sf9 cells with the following hierarchy of affinity: P > aldosterone > 18VP > 18EP >> 18OVP. Functional cotransfection assays in CV-1 cells, using mouse mammary tumor virus promoter as a steroid receptor-inducible DNA target sequence, indicated that the mineralocorticoid activity depends on the nature of the C18 substituent. 18VP and 18EP retained the antimineralocorticoid feature of P, with the following order of activity: P = 18VP > 18EP. The antagonist potency of 18VP was higher (IC50, approximately 10(-8) M) than that of spironolactone (IC50, approximately 7 x 10(-8) M), the most widely used aldosterone antagonist. Interestingly, introducing an oxo function at C18 conferred agonist mineralocorticoid properties; 18OVP behaves as a full agonist (ED50, approximately 10(-7) M) with no antagonist activity. In contrast to what was observed when the three 18- substituted P derivatives acted through hMR, they retained the agonist feature of P through the human P receptor, with the following order of potency: P > 18VP = 18OVP > 18EP. The activity of the 18-substituted P derivatives through the human glucocorticoid receptor was only detected at concentrations higher than 10(-6) M; P and 18VP displayed a partial antagonist activity, whereas 18OVP had a full agonist activity (ED50, approximately 2 x 10(-6) M). Thus, the presence of an oxo group at C18(18OVP) does not change the agonist feature of P through human P receptor, but confers to the ligand an agonist activity through hMR, suggesting that the C18 carbonyl group of aldosterone plays a crucial role in its agonist activity.

This article has been cited by other articles:

				J. Huyet, G. M. Pinon, M. R. Fay, J. Fagart, and M.-E. Rafestin-Oblin Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor Mol. Pharmacol., September 1, 2007; 72(3): 563 - 571. [Abstract] [Full Text] [PDF]

				A.-N. Takeda, G. M. Pinon, M. Bens, J. Fagart, M.-E. Rafestin-Oblin, and A. Vandewalle The Synthetic Androgen Methyltrienolone (R1881) Acts as a Potent Antagonist of the Mineralocorticoid Receptor Mol. Pharmacol., February 1, 2007; 71(2): 473 - 482. [Abstract] [Full Text] [PDF]

				R. K. Bledsoe, K. P. Madauss, J. A. Holt, C. J. Apolito, M. H. Lambert, K. H. Pearce, T. B. Stanley, E. L. Stewart, R. P. Trump, T. M. Willson, et al. A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor J. Biol. Chem., September 2, 2005; 280(35): 31283 - 31293. [Abstract] [Full Text] [PDF]

				M. Quinkler, B. Meyer, W. Oelkers, and S. Diederich Renal Inactivation, Mineralocorticoid Generation, and 11{beta}-Hydroxysteroid Dehydrogenase Inhibition Ameliorate the Antimineralocorticoid Effect of Progesterone in Vivo J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3767 - 3772. [Abstract] [Full Text] [PDF]

				M. Quinkler, C. Bumke-Vogt, B. Meyer, V. Bahr, W. Oelkers, and S. Diederich The Human Kidney Is a Progesterone-Metabolizing and Androgen-Producing Organ J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2803 - 2809. [Abstract] [Full Text] [PDF]

				C. Honer, K. Nam, C. Fink, P. Marshall, G. Ksander, R. E. Chatelain, W. Cornell, R. Steele, R. Schweitzer, and C. Schumacher Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486 Mol. Pharmacol., May 1, 2003; 63(5): 1012 - 1020. [Abstract] [Full Text] [PDF]

				M.-E. Rafestin-Oblin, J. Fagart, A. Souque, C. Seguin, M. Bens, and A. Vandewalle 11beta -Hydroxyprogesterone Acts as a Mineralocorticoid Agonist in Stimulating Na+ Absorption in Mammalian Principal Cortical Collecting Duct Cells Mol. Pharmacol., December 1, 2002; 62(6): 1306 - 1313. [Abstract] [Full Text] [PDF]

				C. Hellal-Levy, J. Fagart, A. Souque, J.-M. Wurtz, D. Moras, and M.-E. Rafestin-Oblin Crucial Role of the H11-H12 Loop in Stabilizing the Active Conformation of the Human Mineralocorticoid Receptor Mol. Endocrinol., August 1, 2000; 14(8): 1210 - 1221. [Abstract] [Full Text]

				M. Quinkler, S. Johanssen, C. Großmann, V. Bähr, M. Müller, W. Oelkers, and S. Diederich Progesterone Metabolism in the Human Kidney and Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 by Progesterone and Its Metabolites J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4165 - 4171. [Abstract] [Full Text]